Description
- Renal Allograft Rejection: ATGAM is prescribed to manage rejection in kidney transplant patients. When used alongside conventional therapy during an episode of rejection, ATGAM helps increase the chances of resolving the acute rejection.
- Aplastic Anemia: ATGAM is also indicated for treating moderate to severe aplastic anemia in patients who are not candidates for bone marrow transplantation.
ATGAM has not been proven effective for patients with aplastic anemia who are eligible for bone marrow transplantation. It is also not recommended for patients with aplastic anemia resulting from conditions like neoplastic disease, storage disease, myelofibrosis, Fanconi’s syndrome, or for those who have been exposed to myelotoxic agents or radiation.
Dosage & Side Effects:Renal Allograft Rejection: For treating renal allograft rejection, the recommended dose is 10 to 15 mg/kg administered intravenously each day for 14 days. If needed, additional doses can be given on alternate days, with a maximum of 21 doses in total.
Aplastic Anemia (Moderate to Severe): For moderate to severe aplastic anemia, the recommended dosage is 10 to 20 mg/kg administered intravenously each day for 8 to 14 days. If needed, additional treatment on alternate days can be continued, totaling up to 21 doses.